Analytical Data
-
Gene name
ADAMTS13
- Application
-
Alternative Names
von Willebrand factor-cleaving protease (vWF-CP) (vWF-cleaving protease) (ADAM-TS 13) (ADAM-TS13) (ADAMTS-13) (Gm710)
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q769J6
-
Expression Region
904-1137aa
-
Molecular Weight
32.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ADAMTS13 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13) is a critical enzyme responsible for the cleavage of von Willebrand factor (VWF), a key player in platelet adhesion and aggregation during hemostasis. Dysregulation or deficiency of ADAMTS13 has been linked to thrombotic thrombocytopenic purpura (TTP), a severe condition characterized by the formation of microclots that can lead to organ damage and potentially life-threatening complications. The recombinant form of ADAMTS13 has emerged as a promising therapeutic candidate aimed at restoring normal VWF processing and mitigating the pathological consequences of its deficiency. Research into the recombinant protein focuses on its production, purification, and functional characterization to ensure that it retains the necessary enzymatic activity to effectively regulate VWF levels in the bloodstream. Studies have shown that administering recombinant ADAMTS13 can help reverse the symptoms of TTP and prevent exacerbation of the condition. Additionally, ongoing investigations are exploring its potential applications in other thrombotic disorders, highlighting the enzyme's importance in maintaining vascular homeostasis. As such, the development of recombinant ADAMTS13 holds significant potential not only for treating patients with TTP but also for broader applications in managing various vascular pathologies associated with dysregulated thrombus formation. This research underscores the critical role of enzyme therapy in advancing treatment strategies for thrombotic conditions.
